- Home
- EWCZ vs EDIT Comparison
EWCZ vs EDIT Comparison
Compare EWCZ & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- EDIT
- Stock Information
- Founded
- EWCZ 2004
- EDIT 2013
- Country
- EWCZ United States
- EDIT United States
- Employees
- EWCZ N/A
- EDIT N/A
- Industry
- EWCZ Package Goods/Cosmetics
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EWCZ Consumer Discretionary
- EDIT Health Care
- Exchange
- EWCZ Nasdaq
- EDIT Nasdaq
- Market Cap
- EWCZ 239.2M
- EDIT 241.9M
- IPO Year
- EWCZ 2021
- EDIT 2016
- Fundamental
- Price
- EWCZ $4.15
- EDIT $3.00
- Analyst Decision
- EWCZ Hold
- EDIT Buy
- Analyst Count
- EWCZ 6
- EDIT 12
- Target Price
- EWCZ $5.50
- EDIT $5.40
- AVG Volume (30 Days)
- EWCZ 375.3K
- EDIT 1.4M
- Earning Date
- EWCZ 11-13-2025
- EDIT 11-03-2025
- Dividend Yield
- EWCZ N/A
- EDIT N/A
- EPS Growth
- EWCZ N/A
- EDIT N/A
- EPS
- EWCZ 0.20
- EDIT N/A
- Revenue
- EWCZ $212,509,000.00
- EDIT $38,901,000.00
- Revenue This Year
- EWCZ N/A
- EDIT N/A
- Revenue Next Year
- EWCZ $2.37
- EDIT N/A
- P/E Ratio
- EWCZ $20.58
- EDIT N/A
- Revenue Growth
- EWCZ N/A
- EDIT N/A
- 52 Week Low
- EWCZ $2.72
- EDIT $0.91
- 52 Week High
- EWCZ $8.91
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- EWCZ 46.34
- EDIT 60.05
- Support Level
- EWCZ $3.83
- EDIT $2.54
- Resistance Level
- EWCZ $3.96
- EDIT $2.84
- Average True Range (ATR)
- EWCZ 0.19
- EDIT 0.20
- MACD
- EWCZ 0.02
- EDIT 0.03
- Stochastic Oscillator
- EWCZ 67.47
- EDIT 89.27
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.